|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Eisai
|
|
gptkbp:activities
|
enhances slow inactivation of voltage-gated sodium channels
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
Vimpat
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:class
|
sodium channel modulator
|
|
gptkbp:clinical_trial
|
Phase III
neuropathic pain
|
|
gptkbp:combatants
|
highly protein-bound
|
|
gptkbp:contraindication
|
hypersensitivity to lacosamide
|
|
gptkbp:developed_by
|
gptkb:UCB_Pharma
|
|
gptkbp:effective_date
|
gptkb:2008
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:formulation
|
oral solution
extended-release tablet
immediate-release tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lacosamide
|
|
gptkbp:indication
|
partial-onset seizures
|
|
gptkbp:ingredients
|
C13 H18 N2 O3
|
|
gptkbp:interacts_with
|
CY P450 inducers
CY P450 inhibitors
|
|
gptkbp:is_atype_of
|
N03 A X18
|
|
gptkbp:is_available_on
|
gptkb:software_framework
gptkb:tablet
injection
|
|
gptkbp:is_used_for
|
treatment of epilepsy
|
|
gptkbp:lifespan
|
13 hours
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
primarily hepatic
|
|
gptkbp:pharmacokinetics
|
linear pharmacokinetics
|
|
gptkbp:provides_information_on
|
gptkb:Epilepsy_Foundation
gptkb:American_Academy_of_Neurology
|
|
gptkbp:research
|
improves quality of life
effective for refractory epilepsy
potential for use in bipolar disorder
reduces seizure frequency
well tolerated in elderly patients
|
|
gptkbp:research_areas
|
gptkb:psychologist
neuropathic pain
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
euphoria
arrhythmia
tremor
cognitive dysfunction
visual disturbances
|
|
gptkbp:type_of
|
175481-36-4
|